A national cohort study of adult participants with and without prior SARS-CoV-2 infection found that there are no objective tests to accurately diagnose post-acute sequelae of SARS-CoV-2 infection (PASC), also known as Long COVID.
Data also suggested that many of the long-term PASC symptoms are due to ongoing inflammation, rather than viral invasion of the affected area. The findings are published in Annals of Internal Medicine.
Researchers from the National Institutes of Health studied more than 10,000 adult patients enrolled in the RECOVER (Researching COVID to Enhance Recovery) trial to investigate clinical laboratory markers of SARS-CoV-2 and PASC. Because a baseline was necessary to compare variables, adults were eligible to participate in the study regardless of prior infection of SARS-CoV-2. The researchers compared questionnaire responses and routine clinical laboratory results from participants to determine if SARS-CoV-2 led to persistent laboratory abnormalities, whether or not symptoms were present. The researchers found that none of the 25 routine clinical laboratory values assessed in the study could serve as a clinically useful biomarker of PASC. Additionally, they found evidence to support the idea that SARS-CoV-2 may contribute to diabetes risk independent of PASC symptoms, a connection that had been made early in the pandemic. Those with prior SARS-CoV-2 also had higher urine albumin to creatinine ratio, a marker of early kidney disease that has been associated with cardiovascular disease in other populations. The data also showed that ongoing inflammation is a potential mechanism underlying anosmia (smell/taste disturbances) and PASC.
